Substance use disorder treatment documentation operates under a privacy framework more restrictive than HIPAA in important ways. The federal regulations at 42 CFR Part 2 — commonly called "Part 2" — impose strict limits on who can receive SUD treatment records and under what circumstances. Clinicians working with SUD presentations must understand these regulations, know how they interact with HIPAA in integrated care settings, and document SUD treatment with the specificity that supports both good clinical practice and appropriate level-of-care determinations.
What 42 CFR Part 2 Covers
Part 2 applies to any program that is federally assisted (directly or through tax-exempt status) and holds itself out as providing, or actually provides, alcohol or drug abuse treatment, diagnosis, or referral. This definition encompasses most addiction treatment programs, substance use disorder specialty services, and clinicians who identify their services as including SUD treatment.
Under Part 2, records that identify a person as having received SUD treatment may not be disclosed to any other party — including other treatment providers, family members, employers, or law enforcement — without the patient's specific written consent. This is stricter than HIPAA, which allows disclosure for treatment, payment, and health care operations without patient consent. With Part 2 records, even confirming to another party that someone is a patient in treatment can be a violation.
Permitted Disclosures Without Patient Authorization
Part 2 does permit some disclosures without patient authorization. Medical emergencies that pose an immediate threat to the patient's life permit disclosure to medical personnel. Research with proper IRB approval, audit and evaluation activities, and court orders meeting specific Part 2 standards also permit disclosure. Communication within a treating program — among providers who are part of the same program and treating the patient — is generally permitted.
The 2020 amendments to Part 2 aligned the regulations more closely with HIPAA in several ways. Patients can now consent once to treatment, payment, and health care operations disclosures using a more HIPAA-like consent framework. The amendments also permitted use of Part 2 records for investigations and prosecutions of serious crimes against patients or third parties, with specific procedural requirements. Despite these changes, Part 2 remains substantially more restrictive than HIPAA in most clinical situations.
Documentation in Integrated Care Settings
Co-occurring disorders — substance use disorders alongside mental health conditions — are the norm rather than the exception in SUD treatment populations. When you are treating a client for both an SUD and a co-occurring psychiatric condition, Part 2 creates documentation challenges: the mental health portions of the record may be shareable under standard HIPAA rules, while the SUD-specific portions require Part 2 authorization.
In integrated care settings, the most practical approach is often to maintain separate consent documentation that meets Part 2 requirements for SUD records specifically. Clearly delineate in your records which information is specifically SUD-related and therefore subject to Part 2. When coordinating with other providers — primary care, psychiatry, other behavioral health — obtain Part 2-compliant authorization forms before sharing SUD treatment records, even if a general HIPAA authorization is already on file.
What to Include in SUD Progress Notes
SUD progress notes should document several specific elements that general mental health progress notes may not emphasize. Substance use since the last session should be documented specifically: what substances, in what quantities, how frequently, and in what contexts. This information is clinically relevant for tracking use patterns, monitoring for relapse, and adjusting treatment. Use the client's own words where possible: "Client reported drinking approximately 6 beers daily for 3 days this week, compared to 0 days the previous week; attributed increase to job stress."
Withdrawal symptoms should be documented when present. For alcohol, sedative, and opioid withdrawal in particular, document any physiological symptoms — tremors, sweating, nausea, elevated heart rate, cravings — and the clinical response (referral for medical evaluation, coordination with prescriber, safety planning regarding withdrawal monitoring).
Document cravings: their intensity (on a 0-10 scale), triggers (people, places, things, emotional states), and the client's current coping strategies for managing craving. Recovery capital — the resources the client has supporting recovery, including sober social support, stable housing, employment, peer support involvement — should be documented and updated as it changes.
ASAM Criteria Documentation for Level of Care
The American Society of Addiction Medicine (ASAM) criteria provide the standard framework for SUD level-of-care determinations. Insurers who pay for SUD treatment — including Medicaid managed care plans — increasingly require documentation of ASAM criteria to authorize level of care. The six ASAM dimensions are: (1) Acute intoxication and/or withdrawal potential; (2) Biomedical conditions and complications; (3) Emotional, behavioral, or cognitive conditions and complications; (4) Readiness to change; (5) Relapse, continued use, or continued problem potential; (6) Recovery and living environment.
When documenting level of care justification, address each relevant dimension with specifics from the client's presentation. A client in intensive outpatient programming (IOP) needs documentation supporting why IOP rather than standard outpatient or residential is clinically appropriate. This requires more than "client needs SUD treatment" — it requires documentation of the client's severity across ASAM dimensions and how that severity supports the current level of care.
Urine Drug Screen Documentation
When urine drug screens (UDS) are part of the treatment protocol, document the results, the clinical interpretation, and the clinical response. A positive UDS result for a substance not disclosed by the client should prompt a clinical conversation documented in the record. Do not simply record "UDS positive for THC" and move on. Document how the result was addressed: "UDS returned positive for THC; client had reported abstinence from cannabis since last session. Discrepancy explored with client in session. Client acknowledged use of a small amount at a social event but had minimized it due to shame. Explored shame and honesty within the therapeutic relationship as clinically relevant to treatment goals."
Negative UDS results should also be documented as part of treatment progress monitoring. When UDS results consistently support the client's self-report, this is clinically meaningful recovery progress worth noting.
Coordination with MAT Providers
Medication-assisted treatment (MAT) — buprenorphine, methadone, naltrexone, and related medications — is increasingly integrated with counseling in SUD treatment. When a client is receiving MAT from a prescriber, document: the medication prescribed, the prescriber's name and contact, the medication's clinical role in the treatment plan, and coordination activities with the prescriber.
Document any client-reported side effects, medication adherence challenges, or concerns about medication efficacy and communicate these to the prescriber. Documentation of coordinated care between the therapist and MAT prescriber supports insurance authorization, demonstrates comprehensive treatment, and creates a record of clinical collaboration when clients have complex presentations.